Eagle Pharmaceut (EGRX) Debt by Year
Eagle Pharmaceut carried $56.2M in long-term debt against $55.3M in cash and equivalents at the end of fiscal year 2022. The table below carries 11 fiscal years, from 2012 to 2022, and the quarters Eagle Pharmaceut has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
EGRX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $56.2M | N/A | $25.1M-25.1% | $33.6M-12.1% | $38.2M-11.1% | $42.9M | $0 | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $55.3M-43.4% | $97.7M-5.3% | $103.2M-6.0% | $109.8M+39.3% | $78.8M-31.3% | $114.7M+117.1% | $52.8M-33.2% | $79.1M+248.0% | $22.7M+117.3% | $10.5M+106.4% | $5.1M |
EGRX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q | Q1'2110-Q | Q4'2010-K | Q3'2010-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $61.9M+120.9% | $68.8M+186.8% | $56.2M | $26.4M+35.6% | $28.0M+31.1% | $24.0M+3.2% | N/A | $19.5M-27.9% | $21.4M-26.0% | $23.3M-24.5% | $25.1M-25.1% | $27.0M-24.3% |
| Cash & Equivalents | $15.4M-58.0% | $21.9M-68.5% | $55.3M-43.4% | $15.4M-84.6% | $36.6M-66.4% | $69.5M-33.9% | $97.7M-5.3% | $99.7M+11.2% | $108.7M+0.5% | $105.2M-47.9% | $103.2M-6.0% | $89.7M-23.5% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Eagle Pharmaceut financials
Frequently Asked Questions
What was Eagle Pharmaceut's long-term debt in fiscal year 2022?
Eagle Pharmaceut carried $56.2M in long-term debt against $55.3M in cash and equivalents at the end of fiscal year 2022.
What was Eagle Pharmaceut's long-term debt in the most recent quarter?
Eagle Pharmaceut (EGRX) reported $61.9M in long-term debt in Q2 2023. This represents an increase of 120.9% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Eagle Pharmaceut (EGRX) reported on that line in every period on record.